Submitted - October 18, 2022 | Revised December 4, 2022 Accepted - December 7, 2022 | | ePublished - December 31, 2022
https://doi.org/10.52733/KCJ22n2-r1
ABSTRACT
Prior to the development of new cancer technologies, metastatic
Renal Cell Carcinoma (mRCC) had a poor prognosis. Fortunately,
advances in treatment are allowing a growing population of
patients to live with advanced or mRCC. While quality of life has
been an area of investigation in this population as treatments
advance, relatively little is known about the specific survivorship
needs experienced by these patients in the modern treatment
era. Using the five survivorship domains defined by the National
Cancer Institute, this narrative review explores the literature
addressing the survivorship needs of patients living with mRCC.
Significant physical, mental, emotional, social and financial
effects of mRCC are herein discussed. By comparing literature
from the pre-combination treatment period to the modern era,
this narrative review of the published literature highlights the
significant gaps in our survivorship knowledge for this unique
and expanding population. Specifically, this review identifies
gaps in understanding of symptom burden, psychological
impact, financial effects, and the particular impact of immunecheckpoint
inhibitor based combination therapies. Here, we
highlight these areas for further research with the hope of
finding strategies to alleviate the effects of mRCC and improve
the quality of life of patients living with metastatic disease.
INTRODUCTION
Kidney cancer is one of the top
10 most common malignancies
affecting the United States
population, with an estimated
81,800 new cases and 14,890 deaths
in 20231. Of these, >80% are renal
cell carcinomas (RCC), which arise
from the renal cortex. Most new
cases are localized or regional at
diagnosis and therefore surgically
curable. However, for the 15% of
cases that are advanced or metastatic,
prognosis was historically poor1.
Fortunately, recent advances
in therapeutic approaches have
resulted in an increasing population
of metastatic RCC (mRCC) patients
with durable responses. Indeed,
the 5-year relative survival rate for
distant-stage RCC was 13.1% in 2004
and, while data are still maturing,
is expected to be 22.9% in 20202.
Given this increased survivorship
observed among mRCC, a shift in
the focus of care is warranted, from
merely living as long as possible with
disease, to living as well as possible
with ongoing disease control. While
quality of life has been a focus of
study in this patient population3,
the specific survivorship needs
of individuals living with mRCC
remain unexplored.
The National Cancer
Institute (NCI) defines survivorship
as a “focus on the health and wellbeing
of a person with cancer from
the time of diagnosis until the end of
life,” addressing the key domains of
“physical, mental, emotional, social,
and financial effects4.” While these
domains are salient to any cancer
patient, the successes of the shifting
treatment landscape for mRCC over
the past 30 years have underlined
their importance in this population.
Early non-chemotherapy approaches
to treating mRCC included cytokinebased
immunotherapy drugs
like interferon-α (IFN-α) and
interleukin-2 (IL-2), though high
toxicity profiles limited use and
long-term survival was infrequent5.
The introduction of the tyrosine
kinase inhibitors (TKIs) sorafenib
and sunitinib in 2006 and 2007
shifted the treatment paradigm
and mRCC patients began to live
longer with their disease. Most
recently, combining immune
checkpoint inhibitors (ICIs) with
or without these targeted agents
has further improved outcomes for
mRCC patients, achieving median
overall survival rates of more than
4 years6. Several clinical trials
have resulted in FDA approvals of
therapies in combination, including
Checkmate 2147, KEYNOTE 4268,
JAVELIN Renal 1019, CLEAR10,
and Checkmate 9ER6, marking a
new era of combination therapy.
Subsequently, a sizable proportion
of patients with advanced RCC
derive durable benefits from
the combination of ICIs and
targeted therapies, achieving
longer periods of progressionfree
survival or remission than
previously possible. Yet we still
know little about the symptom
trajectory and survivorship needs
of this growing patient population.
In line with calls from
the NCI to better understand the
survivorship needs of all patients
living with advanced or metastatic
cancer11, this narrative review of
the published literature examines
what is known about the needs of
mRCC patients using the framework
set out by the NCI definition above.
Given how varied the literature
addressing this population is, we
incorporated the NCI framework
for its simplicity and widespread
recognition. Specifically, we will
examine the literature addressing
the physical, mental, emotional,
social, and financial effects of cancer
in this specific cohort. We compare
and contrast the literature in the
pre-combination treatment period
(before 2018) to the modern era
(after 2018) in order to identify
gaps in survivorship knowledge.
Our primary aim in doing so is
to generate interest in further
research directed at improving
the quality of life for the growing
population of patients living with
mRCC on contemporary therapies.
SURVIVORSHIP
PHYSICAL EFFECTS
Symptom Burden prior to
Combination Therapy
Much of our early understanding
of the symptom burden of mRCC
in the pre-combination therapy
era comes from clinical trials. For
this reason, when Harding and
colleagues attempted to index
symptom burden in RCC patients,
they started by reviewing clinical
trials that included a quality-oflife
assessment or detailed toxicity
evaluation12. Borrowing from the
various instruments used in these
studies, the authors developed a
pilot RCC symptom index, which
they applied in semi-structured
interviews to RCC patients and
their caregivers. Among the mRCC
patients (n=17) they interviewed,
whose treatment exposures were
predominantly single agent targeted
therapies, the five most common
moderate to severe symptoms were
fatigue, weakness, worry, shortness
of breath, and irritability12. While
the resulting symptom index was
largely replaced by the shorter but
similar Functional Assessment of
Cancer Therapy – Kidney Symptom
Index (FKSI)13, this early work
summarized symptom burden in
metastatic patients in the targeted
therapy era. Similarly, Graham
and colleagues used the Edmonton
Symptom Assessment System
(ESAS) to evaluate whether baseline
symptom scores were predictive of
survival in patients with mRCC on
first-line sunitinib. They found a
small but significant trend towards
worse overall survival if baseline
scores were high, but perhaps more
telling for survivorship purposes
were the baseline scores themselves.
At baseline, patients in this cohort
demonstrated high rates of moderate
to severe anxiety (38%), appetite
disturbance (46%), drowsiness
(32%), fatigue (44%), pain (41%),
and poor overall well-being (36%)14.
While few interventions at this
time were directed at improving
symptoms while on treatment,
Milbury and colleagues randomized
an expressive writing intervention
for patients of all stages of RCC
(including 40 metastatic patients)
and found that writing about
thoughts and feelings (expressive
writing) was associated with lower
overall symptom scores compared
to writing about neutral topics15.
Cella et al. investigated
fatigue in metastatic patients
treated with sunitinib. They showed
that fatigue was most severe at time
of treatment initiation and did not
worsen over time16. The FAMOUS
study from Goebell and colleagues
delved deeper into the differences
between physician-assessed and
patient-reported fatigue in mRCC.
Among patients being treated with
sunitinib, bevacizumab, interferon
alpha, temsirolimus, or everolimus,
the degree of fatigue was more
severe when reported by the patient
and increased with progressive
treatment lines, contributing to
lower quality of life in the realms of
emotional, functional and physical
well-being17. To counteract cancerrelated
fatigue in mRCC, Tsimafeyeu
and colleagues evaluated the role of
testosterone for patients on firstline
pazopanib or sunitinib. Male patients with a normal PSA and low
testosterone level were randomized
to receive testosterone with their
targeted therapy or targeted therapy
alone. The study demonstrated
significant improvement in
Functional Assessment of
Chronic Illness Therapy –
Fatigue (FACIT – Fatigue) for the
patients on testosterone without
significant additional toxicities18.
Sexual health was uniquely
described in mRCC patients
by Marcon and colleagues. In
a longitudinal evaluation of
erectile dysfunction among men
with advanced RCC on firstline
targeted therapy, these
investigators demonstrated that
erectile dysfunction worsened and
correlated with worse subjective
patient sexual satisfaction 12
weeks into therapy compared to
baseline19. While this study did
not account for other psychosocial
confounders, it provides an initial
signal that sexual health should be
considered among the survivorship
needs of patients with mRCC.
Symptom Burden in the
Combination Therapy Era
Few studies have specifically
described the symptom burden
of mRCC patients surviving on
combination therapy. Hall and
colleagues surveyed physicians
and patients with mRCC to collect
real-world data about symptoms.
Of the 227 patients being treated
off clinical trials, the majority were
on TKI monotherapy (50.2%),
but nearly half were being treated
with modern regimens (19.4%
on ICI monotherapy, 19.4% on
ICI combination therapy, and the
remainder on other therapies).
On average, patients reported 4.2
symptoms at initial diagnosis and 3.4
symptoms at the time of the study,
with loss of appetite, fatigue, and
nausea occurring most commonly20.
Kastrati and colleagues similarly
surveyed patients with mRCC to
determine the burden of side-effects
of treatment. Again, the majority
(66%) were on TKI monotherapy,
but a substantial minority were
on ICI monotherapy (19.6%) or
combination therapy (14.4%).
Side effects were more frequent
among those taking a TKI (98.4%
vs. 68.4%) with significantly more
diarrhea, taste alteration, appetite
loss, mucositis, and weight loss.
Fatigue was noted both in patients
on TKIs (62.5%) and ICIs (42.1%)21.
Unfortunately, little
additional information in the
published literature describes the
symptom burden of real-world
mRCC patients in the combination
therapy era. To glean more, we
look to randomized clinical trials
of novel pharmaceuticals which, in
addition to gathering information
on traditional endpoints, have
increasingly included Patient
Reported Outcome Measures
(PROMs) that describe the impact of
modern therapies on Health-Related
Quality of Life (HRQoL). Both
general and disease-specific tools
have been developed and validated
to evaluate a combination of
symptoms, function, psychological
health, and overall wellbeing for
those with mRCC, offering promising
approaches to understanding the
patient experience. These tools and
the result of their application to
patients on different therapies have
been expertly reviewed in the TKI
era22,23 as well as in the combination
therapy era24, however they fall short
of being able to identify survivorship
needs in patients. PROMs serve
well in their primary role, which
is to compare the acceptability of
different therapy approaches in
the eyes of the patient, yet with
scales that aggregate symptoms and
experiences into a single score, it is
challenging to isolate independent
treatment-related or diseaserelated
phenomena experienced
by patients as they continue
to survive with their disease.
To illustrate this, we have
compiled the published results from
HRQoL data collected alongside
recent clinical trials for mRCC
(Table 1 & 2). HRQoL results from
Checkmate 21425,26, KEYNOTE
42627, JAVELIN Renal 10124,
CLEAR28, and Checkmate 9ER29
are summarized and, while the
results often indicate improved
or unchanged HRQoL for the
experimental arm compared to
the control, it is nearly impossible
to dissect these scales to identify
intervenable symptom concerns for
patients. A unique exception comes
from application of the European
Organization for the Research and
Treatment of Cancer 30-item Quality
of Life Questionnaire (EORTC
QLQ-C30) in both the CLEAR and
Keynote 426 studies. The phase III
CLEAR study evaluated the efficacy
of lenvatinib with pembrolizumab
and lenvatinib with everolimus
against standard of care sunitinib
for advanced RCC, finding an
overall survival benefit of the first
combination, but not the second10.
Keynote 426 randomized patients
to pembrolizumab with axitinib
or sunitinib and showed a benefit
in progression-free survival and
response rate8. The EORTC QLQ-30,
which includes symptom-specific
subscales, was used for quality of
life evaluation for both studies30.
The CLEAR trial demonstrated
that patients on lenvatinib and
pembrolizumab had worsening in
symptom subscales at 46 weeks
compared to baseline for fatigue,
nausea and vomiting, pain, appetite
loss, and diarrhea28. While Keynote
426 only presented data for the
nausea and vomiting and diarrhea
symptom subscales, we saw that those
patients on combination axitinib
and pembrolizumab at 30 weeks had
worsening of their nausea/vomiting
and diarrhea. Of the patients on the
combination therapy arm, fewer
than 10% had improvement in these
symptoms, 25% had worsening of
their nausea and vomiting, and
50% had worsening diarrhea27.
Cardiotoxicity
The cardiac effects of small molecule
agents targeting vascular endothelial
growth factor receptor (VEGFR)
and platelet-derived growth factor
receptor (PDGFR) have been a
focus of study since clinical trials
in mRCC identified hypertension
and decreased ejection fraction as
potential adverse effects of use31–
33. Investigators from Stanford
University described the incidence of
cardiotoxicity among 159 patients on
such targeted therapies, noting that
73% developed some form of cardiac
toxicity. While the majority were
diagnosed with new or worsening
hypertension, 16% experienced
decreased ejection fraction and 31%
developed overt heart failure34. In
Taiwan, the incidence rate of major
adverse cardiovascular events
(MACE) was 6.65 per 100 personyears
for individuals on targeted
therapies, compared to 3.36 per 100
person-years on cytokine therapy
(IL-2 or IFN). In this cohort,
presence of a baseline cardiac
comorbidity was an independent
risk factor for developing
MACE35. A review by Franczyk
and colleagues summarized the
published cardiovascular side
effects of sorafenib, sunitinib, and
pazopanib, implicating the drugs
in development of hypertension,
left ventricular function decline,
cardiac ischemia or infarction, and
heart failure36. Even newer TKIs,
such as cabozantinib, have been
connected to cardiac dysfunction37.
A prospective multicenter trial of
22 mRCC patients on cabozantinib
demonstrated a risk of developing
left ventricular systolic dysfunction 6
months after treatment initiation38.
There has been limited study of
the cardiac effects of combination
therapies (dual ICI or TKI/
ICI) outside of clinical trials. A
prospective study that compared
mRCC patients receiving TKI with
or without ICI (n=28) to patients
with localized RCC (n=29) and
healthy controls (n=20) found that
patients with mRCC and localized
RCC had a significantly lower
mean ejection fraction at baseline
compared to controls, but did not
otherwise find significant changes
in echocardiographic findings,
clinical incidence of heart failure,
or cardiac blood biomarkers in the
6 months of follow up39. It is also
known, from the immunotherapy
related adverse events (IRAE)
literature and from case reports in
mRCC40,41, that myocarditis and
ventricular arrhythmias can happen
on combination therapy, however
their overall incidence is rare.
SURVIVORSHIP MENTAL
EFFECTS
While there is little known about
the cognitive effects of combination
therapy in mRCC, data suggests
that patients on earlier RCC
treatment modalities demonstrated
negative impacts on cognition. An
early review of cognitive effects of
high-dose IL-2 therapy described
“cognitive fatigue” as a combination
of lethargy, confusion, inability to
focus, sleep insufficiency, decreased
memory and limited attention
span. Prevalence of such mental
changes was estimated to be 80%
among patients receiving IL-2
treatment for mRCC42. Mental
deterioration was noted in a much
smaller proportion (13%) of patients
treated with IFN-α for mRCC43. In
the TKI era, Miller and colleagues
demonstrated that mRCC was a risk
factor for developing mild cognitive
impairment or dementia (MCI/D).
Among 2533 patients with mRCC in
the SEER database from 2007-2015,
having mRCC was associated with
a larger than 8-fold greater hazard
of developing MCI/D. In contrast,
age was a much weaker predictor,
with a hazard ratio of 1.05 per 1-year
increase in age44. In a prospective
study of patients starting antiangiogenic
therapy as first- or
second-line therapy for mRCC,
Joly and colleagues demonstrated
cognitive decline in 31% of patients,
and increased fatigue in all patients
except one. While a relationship
between cognitive complaints and
fatigue was noted, there was no
statistical association between
objective cognitive decline and
fatigue45. These studies suggest
that cognition can be compromised
in the mRCC survivorship period,
though whether these are disease- or
treatment-mediated, and whether
cognition is impacted by combination
therapies, remains unclear.
SURVIVORSHIP
EMOTIONAL EFFECTS
The psycho-emotional impact
of mRCC, while far from wellunderstood,
has garnered attention
in the pre-combination therapy
era. Scientific inquiries have
reported widely varied prevalence
estimates for psychological distress
among patients with mRCC, with
estimates as high as 77% and as low
as 20.7%46,47. Major contributors
to distress are described as pain,
fatigue, and financial comorbidities,
and evidence suggests that younger,
unmarried, female populations
with non-clear cell histology may
be at higher risk47,48. However,
it is clear that work in this area
is limited, as a recent systematic
review identified only three
publications discussing distress
in metastatic RCC populations49.
There is some evidence
that patient outlook can influence
the development of psychological
symptoms. Milbury and colleagues
reported that mRCC patients with
high treatment optimism, even
if unrealistic, experienced a less
severe decline in quality of life
than those with low optimism
over the course of a clinical trial50.
Prinsloo et al. linked mental outlook
directly to health by reporting an
association between positive affect
and biologic markers in mRCC
patients51. Bergerot and colleagues
extended this understanding of
patient attitudes by examining
points of frustration for patients
with mRCC. They conducted a
survey among 450 patients with
RCC and found that 71.5% reported
frustration, with common sources
identified as fear of recurrence and
distrust of the cancer care system52.
Depressive symptoms
have also been examined in mRCC
patients in the pre-combination
therapy era, with 23% of 217
mRCC patients screening positive
for depression symptoms on
the Centers for Epidemiologic
Studies – Depression (CES-D)
questionnaire in a study from Cohen
and colleagues. The presence of
depression was notably found to be
associated with decreased survival
and linked to dysregulation of
cortisol and biological markers of
inflammation53. Despite a relatively
low prevalence, depression has been
shown to have devastating impacts
in this population. According to a
Surveillance, Epidemiology, and
End Results (SEER) analysis of
genitourinary cancer patients from
1988-2010, there were an estimated
26 suicides per 100,000 personyears
in the RCC population overall
and 90 per 100,000 person-years
in those with metastatic disease.
Compared to suicide rates in the
general US population, those with
kidney cancer experience more
than two-times as many suicides in
the 0 to 5 years after diagnosis54. A
second SEER analysis of cause of
death in patients diagnosed with
RCC from 2005-2015 showed that
a majority of metastatic patients
still die from their disease (84.65%),
however metastatic patients had a
more than three-fold higher risk of
death from suicide than patients
with less advanced stages of RCC55.
These studies suggest that mental
health continues to be inadequately
addressed in mRCC patients.
Far fewer psychological
investigations have been conducted
in the combination therapy era.
Investigators have explored changes
in perception of cure among patients
on ICI therapy for genitourinary
malignancies, including mRCC.
For this population, ICI can be
very effective, however not all will
not experience cure. Bergerot and
colleagues showed that accurate
perceptions of cure improved over
time, suggesting improvement in
patient provider communication,
and that accurate expectations
were associated with lower rates of
anxiety. Inaccurate expectations
were associated with more severe
side effects and worse selfreported
performance status56.
How the uncertainty of a durable
response with combination
therapy impacts emotional
states in patients with mRCC
continues to be largely unexplored.
SURVIVORSHIP
FINANCIAL EFFECTS ON
PATIENTS AND SOCIETY
Most research addressing social
aspects of mRCC survivorship is
centered on the financial impact
of living with advanced disease. In
the pre-combination therapy era,
a Danish registry study compared
the economic impact of early
immunotherapy approaches (IL-
2 and IFN-α) to targeted therapy.
The investigators found that
health care costs per patient were
not significantly different in the
immunotherapy period (2002-
2005) compared to the targeted
therapy period (2006-2009), but the
distribution of costs differed. In the
targeted therapy era, inpatient costs
were lower, but outpatient, radiology
and drug costs were higher57.
A string of cost effectiveness
analyses in the pre-combination
therapy era primarily used clinical
trial data to compare the economic
value of various treatment options.
Sorafenib was not found to be cost
effective compared to supportive
care in second-line treatment58. In
England, cabozantinib was found to
be less expensive and more effective
than nivolumab in the secondline59
and neither the combination
of bevacizumab, interferon and
sunitinib nor interferon alone
were found to be cost-effective60.
A Swedish study applied similar
concepts to real-world data and
found that targeted therapy for mRCC
patients was cost effective compared
to prior treatment modalities, with
increased efficiency over time61.
A major concern in the
combination therapy era is
financial toxicity to the patient,
given the high price of ICI and
TKI combination therapy and
their potentially indefinite use in
patients with durable responses.
Estimates in Europe suggest that
costs are increasing among RCC
survivors as a whole62. In the United
States, a Kidney Cancer Research
Alliance (KCCure) mediated survey
assessed financial burden in the
combination therapy era and found
that financial hardship was low
(15%) among respondents, though
the sample was predominantly
white (91%), most had an advanced
degree (52.9%), and few (17%)
had an annual household income
<$50,00063. Initial estimates from
Choueiri and colleagues suggested
that combination nivolumab and
ipilimumab was associated with
an incremental cost of $91,000
and a gain of 1.3 quality adjusted
life years (QALYs) compared to
sunitinib. They showed that this
was more cost effective than the
combination of pembrolizumab with
axitinib, which had an incremental
cost of $333,000 for a gain of 0.5
QALY64. Unfortunately, additional
information about the costs of care
in the combination era are lacking.
CONCLUSIONS
As patients with mRCC continue to
see increased survival, it becomes
essential to refocus our approach
to care with a survivorship lens.
Applying said lens to the mRCC
literature reveals that most
patients have a significant physical
symptom burden, with fatigue, loss
of appetite, and gastrointestinal
upset being most common. We
also see significant mental health
and cognitive impacts. Finally,
financial effects seem to contribute
to distress among patients as they
continue to survive with advanced
disease for longer periods of time.
While this review effectively
summarizes the literature
addressing survivorship for mRCC
patients, there are limitations. First,
we pursued a narrative instead of a
systematic review, which permits
the possible exclusion of relevant
publications from our account.
However, given the new lens offered
by this review, a systematic search
was considered too broad to be
feasible. Further, due the nature
of the review, we do not comment
on the quality of the data included.
This narrative review reveals that
there are still many unknowns about
the nature of the physical, mental,
emotional, social, and financial
impact of mRCC, especially in
the era of combination therapy.
Given the growing population
of patients living with advanced
disease, it becomes imperative to
develop a better understanding
of these issues, and how we can
alleviate them, with future study.
AUTHORS DISCLOSURES:
NVB declares no conflict of interest that
could be perceived as prejudicing the
impartiality of the research reported.
MSS declares no conflict of interest that
could be perceived as prejudicing the
impartiality of the research reported.
AD declares no conflict of interest that
could be perceived as prejudicing the
impartiality of the research reported.
AJP declares no conflict of interest that
could be perceived as prejudicing the
impartiality of the research reported.
FUNDING
This research did not receive any
specific grant from any funding
agency in the public, commercial or
not-for-profit sector.
REFERENCES
1. Kidney and Renal Pelvis Cancer —
Cancer Stat Facts. Accessed November 9, 2023.
https://seer.cancer.gov/statfacts/html/kidrp.
html
2. SEER*Explorer Application. Accessed
September 2, 2023. https://seer.cancer.gov/
statistics-network/explorer/application.html?
3. Litwin MS, Fine JT, Dorey F, Figlin
RA, Belldegrun AS. Health Related Quality
of Life Outcomes in Patients Treated for
Metastatic Kidney Cancer: A Pilot Study. J Urol.
1997;157(5):1608-1612. doi:10.1016/S0022-
5347(01)64807-9
4. Definition of survivorship - NCI
Dictionary of Cancer Terms - NCI. Published
February 2, 2011. Accessed April 7, 2023. https://
www.cancer.gov/publications/dictionaries/
cancer-terms/def/survivorship
5. Motzer RJ, Russo P. Systemic therapy
for renal cell carcinoma. J Urol. 2000;163(2):408-
417.
6. Motzer RJ, Powles T, Burotto M, et al.
Nivolumab plus cabozantinib versus sunitinib
in first-line treatment for advanced renal cell
carcinoma (CheckMate 9ER): long-term followup
results from an open-label, randomised,
phase 3 trial. Lancet Oncol. 2022;23(7):888-
898. doi:10.1016/S1470-2045(22)00290-X
7. Motzer RJ, Tannir NM, McDermott
DF, et al. Nivolumab plus Ipilimumab versus
Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2018;378(14):1277-1290.
doi:10.1056/NEJMoa1712126
8. Rini BI, Plimack ER, Stus V, et al.
Pembrolizumab plus Axitinib versus Sunitinib
for Advanced Renal-Cell Carcinoma. N Engl
J Med. 2019;380(12):1116-1127. doi:10.1056/
NEJMoa1816714
9. Motzer RJ, Penkov K, Haanen J, et
al. Avelumab plus Axitinib versus Sunitinib
for Advanced Renal-Cell Carcinoma. N Engl
J Med. 2019;380(12):1103-1115. doi:10.1056/
NEJMoa1816047
10. Motzer R, Alekseev B, Rha SY, et al.
Lenvatinib plus Pembrolizumab or Everolimus
for Advanced Renal Cell Carcinoma. N Engl J
Med. 2021;384(14):1289-1300. doi:10.1056/
NEJMoa2035716
11. Mollica MA, Smith AW, Tonorezos E,
et al. Survivorship for Individuals Living With
Advanced and Metastatic Cancers: National
Cancer Institute Meeting Report. JNCI J Natl
Cancer Inst. 2021;114(4):489-495. doi:10.1093/
jnci/djab223
12. Harding G, Cella D, Robinson D,
Mahadevia PJ, Clark J, Revicki DA. Symptom
burden among patients with renal cell
carcinoma (RCC): content for a symptom
index. Health Qual Life Outcomes. 2007;5:34.
doi:10.1186/1477-7525-5-34
13. Rao D, Butt Z, Rosenbloom S, et al.
A Comparison of the Renal Cell Carcinoma–
Symptom Index (RCC-SI) and the Functional
Assessment of Cancer Therapy–Kidney
Symptom Index (FKSI). J Pain Symptom
Manage. 2009;38(2):291-298. doi:10.1016/j.
jpainsymman.2008.08.013
14. Graham J, Gingerich J, Lambert P,
Alamri A, Czaykowski P. Baseline Edmonton
Symptom Assessment System and survival in
metastatic renal cell carcinoma. Curr Oncol
Tor Ont. 2018;25(4):e319-e323. doi:10.3747/
co.25.3935
15. Milbury K, Spelman A, Wood C, et
al. Randomized Controlled Trial of Expressive
Writing for Patients With Renal Cell Carcinoma.
J Clin Oncol. 2014;32(7):663-670. doi:10.1200/
JCO.2013.50.3532
16. Cella D, Davis MP, Négrier S, et al.
Characterizing fatigue associated with sunitinib
and its impact on health-related quality of life
in patients with metastatic renal cell carcinoma.
Cancer. 2014;120(12):1871-1880. doi:10.1002/
cncr.28660
17. P J G, A M, L M, et al. A crosssectional
investigation of fatigue in advanced
renal cell carcinoma treatment: results from the
FAMOUS study. Urol Oncol. 2014;32(3):362-
370. doi:10.1016/j.urolonc.2013.09.009
18. Tsimafeyeu I, Tishova Y, Zukov R,
Borisov P, Bondarenko A, Zakurdaeva K.
Testosterone for Managing Treatment-related
Fatigue in Patients With Metastatic Renal Cell
Carcinoma: A Phase 2 Randomized Study
FARETES. Am J Clin Oncol. 2021;44(4):137-
142. doi:10.1097/COC.0000000000000797
19. Marcon J, Trottmann M, Rodler S, et
al. Impact of antiangiogenic treatment on the
erectile function in patients with advanced renal
cell carcinoma. Andrologia. 2021;53(1):e13881.
doi:10.1111/and.13881
20. Hall J, Zanotti G, Kim R, et al. Realworld
symptoms, disease burden, resource use
and quality of life in US patients with advanced
renal cell cancer. Future Oncol Lond Engl.
2021;17(17):2169-2182. doi:10.2217/fon-2020-
1266
21. Kastrati K, Mathies V, Kipp AP,
Huebner J. Patient-reported experiences with
side effects of kidney cancer therapies and
corresponding information flow. J Patient-Rep
Outcomes. 2022;6(1):126. doi:10.1186/s41687-
022-00533-z
22. Cella D. Beyond traditional
outcomes: improving quality of life in patients
with renal cell carcinoma. The Oncologist.
2011;16 Suppl 2(Suppl 2):23-31. doi:10.1634/
theoncologist.2011-S2-23
23. Lambea J, Hinojo C, Lainez N, et al.
Quality of life and supportive care for patients
with metastatic renal cell carcinoma. Cancer
Metastasis Rev. 2012;31 Suppl 1:S33-39.
doi:10.1007/s10555-012-9357-9
24. Nolla K, Benjamin DJ, Cella D.
Patient-reported outcomes in metastatic renal
cell carcinoma trials using combinations versus
sunitinib as first-line treatment. Nat Rev Urol.
2023;20(7):420-433. doi:10.1038/s41585-023-
00747-w
14 Kidney Cancer Journal | 22 (1) MAR 2024 Kidney-Cancer-Journal.com
25. Cella D, Grünwald V, Escudier B, et
al. Patient-reported outcomes of patients with
advanced renal cell carcinoma treated with
nivolumab plus ipilimumab versus sunitinib
(CheckMate 214): a randomised, phase 3 trial.
Lancet Oncol. 2019;20(2):297-310. doi:10.1016/
S1470-2045(18)30778-2
26. Cella D, Choueiri TK, Hamilton M,
et al. Health-related quality of life (HRQoL) in
previously untreated patients with advanced
renal cell carcinoma (aRCC) in CheckMate
214: Five-year follow-up results. J Clin Oncol.
2022;40(6_suppl):307-307. doi:10.1200/
JCO.2022.40.6_suppl.307
27. Bedke J, Rini BI, Plimack ER, et al.
Health-related Quality of Life Analysis from
KEYNOTE-426: Pembrolizumab plus Axitinib
Versus Sunitinib for Advanced Renal Cell
Carcinoma. Eur Urol. 2022;82(4):427-439.
doi:10.1016/j.eururo.2022.06.009
28. Motzer R, Porta C, Alekseev B, et
al. Health-related quality-of-life outcomes in
patients with advanced renal cell carcinoma
treated with lenvatinib plus pembrolizumab
or everolimus versus sunitinib (CLEAR): a
randomised, phase 3 study. Lancet Oncol.
2022;23(6):768-780. doi:10.1016/S1470-
2045(22)00212-1
29. Cella D, Motzer RJ, Suarez C, et
al. Patient-reported outcomes with first-line
nivolumab plus cabozantinib versus sunitinib
in patients with advanced renal cell carcinoma
treated in CheckMate 9ER: an open-label,
randomised, phase 3 trial. Lancet Oncol.
2022;23(2):292-303. doi:10.1016/S1470-
2045(21)00693-8
30. Aaronson NK, Ahmedzai S, Bergman
B, et al. The European Organization for Research
and Treatment of Cancer QLQ-C30: a qualityof-
life instrument for use in international
clinical trials in oncology. J Natl Cancer Inst.
1993;85(5):365-376. doi:10.1093/jnci/85.5.365
31. Motzer RJ, Hutson TE, Tomczak
P, et al. Sunitinib versus Interferon Alfa in
Metastatic Renal-Cell Carcinoma. N Engl
J Med. 2007;356(2):115-124. doi:10.1056/
NEJMoa065044
32. Escudier B, Eisen T, Stadler WM, et
al. Sorafenib in Advanced Clear-Cell Renal-Cell
Carcinoma. N Engl J Med. 2007;356(2):125-
134. doi:10.1056/NEJMoa060655
33. Choueiri TK, Hessel C, Halabi S,
et al. Cabozantinib versus sunitinib as initial
therapy for metastatic renal cell carcinoma of
intermediate or poor risk (Alliance A031203
CABOSUN randomised trial): Progressionfree
survival by independent review and
overall survival update. Eur J Cancer Oxf
Engl 1990. 2018;94:115-125. doi:10.1016/j.
ejca.2018.02.012
34. Hall PS, Witteles R, Srinivas S,
Harshman LC. Incidence and severity of
cardiotoxicity in metastatic renal cell carcinoma
(RCC) patients treated with targeted therapies.
J Clin Oncol. 2012;30(15_suppl):4610-4610.
doi:10.1200/jco.2012.30.15_suppl.4610
35. Chen DY, Liu JR, Tseng CN, et
al. Major Adverse Cardiovascular Events
in Patients With Renal Cell Carcinoma
Treated With Targeted Therapies. JACC
CardioOncology. 2022;4(2):223-234.
doi:10.1016/j.jaccao.2022.05.002
36. Franczyk B, Rysz J, Ławiński J,
Ciałkowska-Rysz A, Gluba-Brzózka A.
Cardiotoxicity of Selected Vascular Endothelial
Growth Factor Receptor Tyrosine Kinase
Inhibitors in Patients with Renal Cell
Carcinoma. Biomedicines. 2023;11(1):181.
doi:10.3390/biomedicines11010181
37. Buttar C, Lakhdar S, Nassar M,
Landry I, Munira M. Cabozantinib-Induced
Severe Cardiac Dysfunction: A Case Report and
a Systematic Review of the Literature. Cureus.
2022;14(4):e23740. doi:10.7759/cureus.23740
38. Iacovelli R, Ciccarese C, Fornarini
G, et al. Cabozantinib-related cardiotoxicity:
a prospective analysis in a real-world cohort
of metastatic renal cell carcinoma patients.
Br J Clin Pharmacol. 2019;85(6):1283-1289.
doi:10.1111/bcp.13895
39. Lee K, Lindenfeld L, Echevarria M,
et al. Cardiovascular profile of contemporary
treatments of renal cell carcinoma: A
single-center prospective study. Int J
Cardiol. 2023;380:40-46. doi:10.1016/j.
ijcard.2023.03.040
40. Savarapu P, Abdelazeem B, Isa S,
Kesari K, Kunadi A. Ipilimumab and Nivolumab
induced ventricular tachycardia in a patient with
metastatic renal cell carcinoma. J Community
Hosp Intern Med Perspect. 2021;11(6):874-876.
doi:10.1080/20009666.2021.1965708
41. Miyauchi Y, Naito H, Tsunemori H,
et al. Myocarditis as an immune-related adverse
event following treatment with ipilimumab and
nivolumab combination therapy for metastatic
renal cell carcinoma: a case report. J Med Case
Reports. 2021;15(1):508. doi:10.1186/s13256-
021-03097-6
42. Mann TK, Dail RB, Bailey
DE. Cognitive and Affective Symptoms
Experienced by Cancer Patients Receiving
High-Dose Intravenous Interleukin 2 Therapy:
An Integrative Literature Review. Cancer
Nurs. 2016;39(5):349-357. doi:10.1097/
NCC.0000000000000317
43. Merimsky O, Reider-Groswasser I,
Inbar M, Chaitchik S. Interferon-related mental
deterioration and behavioral changes in patients
with renal cell carcinoma. Eur J Cancer Oxf Engl
1990. 1990;26(5):596-600. doi:10.1016/0277-
5379(90)90086-9